Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.

Blood advances - 12 Jun 2018

Kubasch Anne Sophie, Wehner Rebekka, Bazzurri Serena, Tunger Antje, Stasik Sebastian, Garzarolli Marlene, Meinel Jörn, Baretton Gustavo, Meier Friedegund, Thiede Christian, Schmitz Marc, Platzbecker Uwe

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antibodies, Monoclonal, Humanized
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Neoplasm Proteins

Share to Neoplasms, Second Primary

Source

Open in PubMed Open full text

Identifiers

PMID: 29844203
DOI: 10.1182/bloodadvances.2017014811
PMCID: PMC5998917

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.PMID 29844203Read ↗

Major therapeutic developments and current challenges in advanced melanoma.Semantic proximity Read ↗

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.Semantic proximity Read ↗

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.Semantic proximity Read ↗

Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanomaSemantic proximity Read ↗

Reduction of soluble PD-L1 by plasma exchange and radiation therapy in patients with refractory melanoma re-sensitizes to immunotherapy.Semantic proximity Read ↗

Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome.Semantic proximity Read ↗

Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).Semantic proximity Read ↗

Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.Semantic proximity Read ↗

Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with IpilimumabSemantic proximity Read ↗

[Dramatic response to encorafenib plus binimetinib in a patient with leukemoid reaction from metastatic melanoma.]Semantic proximity Read ↗

Switch from dabrafenib/trametinib combination therapy to encorafenib/binimetinib combination therapy with transition of serum lactate dehydrogenase level in melanoma: A case report.Semantic proximity Read ↗

Upfront combination therapy in anti-melanoma differentiation-associated gene 5 (MDA5) associated rapidly progressive interstitial lung disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.